
OxDX provides clinicians and laboratories with ultra-fast pathogen identification in under a minute using optical imaging and ML. The company combines a universal fluorescent labelling approach with single-molecule and super-resolution fluorescence microscopy to generate high-resolution images of whole samples. Those images are analysed by trained neural networks and machine-learning models to classify pathogens rapidly. OxDX operates as a diagnostic technology company focused on clinical and laboratory customers and research use cases. The company is a spinout from the University of Oxford developing rapid diagnostics to enable broader clinical questioning about infection causes.

OxDX provides clinicians and laboratories with ultra-fast pathogen identification in under a minute using optical imaging and ML. The company combines a universal fluorescent labelling approach with single-molecule and super-resolution fluorescence microscopy to generate high-resolution images of whole samples. Those images are analysed by trained neural networks and machine-learning models to classify pathogens rapidly. OxDX operates as a diagnostic technology company focused on clinical and laboratory customers and research use cases. The company is a spinout from the University of Oxford developing rapid diagnostics to enable broader clinical questioning about infection causes.
What they do: AI-powered ultra-fast pathogen identification using super-resolution/single-molecule fluorescence microscopy and ML
Founded: 2021 (University of Oxford spinout)
Headquarters: Headington, Oxfordshire, United Kingdom
Stage / funding: Pre-seed (£2.6M announced Feb 15, 2022)
Employees: About 15
Rapid infectious-disease diagnostics for clinical and laboratory customers and research use cases.
2021
Biotechnology
£2.6M
Participation from Science Creates Ventures (SCVC); announced 15 February 2022
“Co-led by IQ Capital and Ahren Innovation Capital with participation from Science Creates Ventures (SCVC)”